Does Methotrexate Raise Cancer Risk Long-Term?
Methotrexate, used for rheumatoid arthritis, psoriasis, and some cancers, suppresses the immune system and DNA synthesis, which can theoretically promote cancer development over years of use. Studies show mixed results: some detect small increases in lymphoma or skin cancer risk, especially at higher doses or with long-term exposure, while others find no overall elevation after adjusting for underlying conditions like RA, which independently raise cancer odds.[1][2]
A 2017 meta-analysis of over 13,000 RA patients found methotrexate users had a 28% higher lymphoma risk compared to non-users (RR 1.28, 95% CI 1.02-1.61), but risk dropped after stopping the drug.[3] Large cohort studies, like one from the British Society for Rheumatology tracking 13,000 patients over 10+ years, reported no significant rise in solid tumors or overall malignancy.[4]
What Cancers Are Linked?
Lymphomas top the list, particularly in autoimmune patients—methotrexate-associated lymphoproliferative disorders often regress upon discontinuation.[5] Non-melanoma skin cancers appear slightly elevated (OR 1.45 in some reviews), tied to UV exposure and immunosuppression.[6] No strong links to breast, lung, or colorectal cancers; leukemia risk seems neutral or lower in low-dose regimens.[2]
How Do Dose and Duration Factor In?
Low weekly doses (7.5-25 mg) for arthritis carry minimal risk over decades, per FDA labeling and post-marketing data.[7] High-dose IV use in cancer treatment shows transient DNA damage but no proven long-term carcinogenesis in survivors.[8] Cumulative exposure over 5-10 years correlates with higher lymphoma odds in RA cohorts.[3]
Compared to Other DMARDs or Biologics?
Methotrexate alone has lower malignancy signals than TNF inhibitors like adalimumab, which double lymphoma risk in some RA studies (SIR 2.0-3.0).[9] Combinations with biologics amplify risks slightly, but benefits often outweigh hazards in severe disease.[4]
What Do Guidelines and Monitoring Say?
ACR and EULAR recommend annual skin checks and lymphoma vigilance for long-term users, but don't contraindicate based on cancer risk alone.[10] Baseline malignancy screening applies; avoid in active cancer history. Patient registries like CORRONA track real-world outcomes, showing 1-2% annual event rates unchanged by methotrexate.[11]
Sources
[1] Habel et al., Arthritis Rheum 2010 (PubMed)
[2] Mariette et al., Ann Rheum Dis 2017 (PubMed)
[3] Hellgren et al., Arthritis Rheumatol 2017 (PubMed)
[4] Dixon et al., Arthritis Rheum 2010 (PubMed)
[5] WHO Classification of Tumours, IARC 2017
[6] Pelclova et al., J Rheumatol 2017 (PubMed)
[7] FDA Methotrexate Label 2023
[8] Widemann et al., Cancer Treat Rev 2014 (PubMed)
[9] Solomon et al., JAMA 2019 (PubMed)
[10] Smolen et al., Ann Rheum Dis 2020 (PubMed)
[11] Harrold et al., Arthritis Care Res 2018 (PubMed)